Introduction
Wuzhi capsule (WZ) is a preparation derived from the ethanol extract of Schisandra sphenanthera and is broadly utilized in scientific follow in China to guard liver perform in sufferers with continual hepatitis or liver dysfunction. WZ attenuates liver steatosis and irritation throughout the improvement of nonalcoholic fatty liver illness.1
Statins are broadly used within the secondary and first prevention of atherosclerotic heart problems. Moreover, a meta-analysis confirmed useful results of statin use in lowering inflammatory markers in sufferers with metabolic syndrome and associated problems.2 An exploratory evaluation of knowledge from 5 trials confirmed that rosuvastatin 10 mg was extremely efficient in comprehensively modifying the lipid profile of sufferers with excessive low-density lipoprotein ldl cholesterol and metabolic syndrome.3 Statins can considerably enhance the estimated fee of glomerular filtration, cut back serum creatinine, lower the extent of high-sensitivity C-reactive proteins and reduce the extent of blood lipids within the remedy of diabetic nephropathy, thus lowering the inflammatory response and defending the kidney.4 Stain remedy has favorable results in hypercholesterolemic sufferers with regard to the atherogenic dyslipidemia related to metabolic syndrome. Rosuvastatin had essentially the most favorable impact on the general atherogenic lipid profile of metabolic syndrome.5 Threat lowering statin remedy is advisable for nearly all sufferers with kind 2 diabetes mellitus (DM2) at 40 years of age or older no matter ldl cholesterol stage.6 Clinicians ought to think about intensifying statin regimens to enhance dyslipidemia management in statin-treated sufferers with DM2.7
Hepatic opposed results are essentially the most recognized opposed results induced by statins.8 In roughly 1% of sufferers, statins trigger asymptomatic and dose-related elevations in serum transaminases higher than 3 occasions the higher restrict of regular. Avoiding statin use is pointless in sufferers with nonalcoholic fatty liver illness, nonalcoholic steatohepatitis, compensated cirrhosis, and compensated continual liver illness if there’s a clear indication.9 Statins can delay the development of hepatic fibrosis, stop hepatic decompensation in cirrhosis, and cut back all-cause mortality in sufferers with continual liver illness.10
In scientific follow, WZ and statins could be prescribed collectively to stop statin-induced liver harm, to proceed statin use in delicate liver insufficiency, or to deal with continual liver illnesses similar to nonalcoholic fatty liver illness. Schisandrin B, one of many foremost lively elements of WZ, interferes with the in vitro uptake of rosuvastatin mediated by the natural anion transporting polypeptide 1B1 (OATP1B1) and considerably inhibits the transport perform of the transgenic breast most cancers resistance protein (BCRP) cell line.11,12 Rosuvastatin is a typical substrate of each OATP1B1 and BCRP.13,14 Due to this fact, there’s a risk of herb-drug interplay between WZ and rosuvastatin in vivo. Nonetheless, literature on this challenge isn’t at the moment out there. On this research, we explored the consequences of WZ on the pharmacokinetics of rosuvastatin in Sprague-Dawley (SD) rats and tried to advertise rational use of statins.
Strategies
Reagents, Supplies, and Chemical compounds
The reference requirements for calcium rosuvastatin (purity ≥98%, lot A29O7E23856) have been provided by Shanghai Yuanye Bio-Expertise Co., Ltd. (Shanghai, China.). The reference requirements of lovastatin (purity>98%, lot L1507002) have been used as the inner customary (IS) for chromatographic evaluation and have been bought from Shanghai Aladdin Bio-Chem Expertise Co., Ltd. Ultrapure water was obtained from a Milli-Q Plus water purification system (Millipore, Bedford, MA, USA). Methanol, acetonitrile, and formic acid have been of HPLC grade and have been bought from Merck, Germany.
Instrumentation and LC -MS-MS Situations
A liquid chromatography, electrospray ionization, tandem mass spectrometry (LC-ESI-MS/MS) system consists of an Agilent 1260 HPLC system (Agilent Applied sciences Inc., USA), AB SCIEX API 4000+TM triple-quadruple mass spectrometer (Utilized Biosystems, USA).
Separation was achieved on a 3.5 μm (2.1 mm ×100 mm, i.d.) Zorbax Eclipse Plus C18 column (Agilent Applied sciences Inc., USA). The cell section was a combination of water (containing 0.1% formic acid)- acetonitrile (containing 0.1% formic acid) (10:90, v/v) pumped at a move fee of 0.3 mL/min. Column oven was saved at 20°C. The autosampler was set at 4°C. Whole run time was 6.5 min for every injection. Mass spectrometric evaluation was carried out within the positive-ion (ESI) and a number of response monitoring (MRM) acquisition mode. The mass spectrometer was set to observe the transitions of precursors to product ions as follows: m/z 482.0→258.2 for rosuvastatin and m/z 427.4→325.3 for IS. Ion supply fuel 1 (GS1): 482.7kPa; curtain fuel: 206.9kPa; collision fuel (CAD): 34.5kPa; ion supply fuel 2 (GS2): 482.7kPa. The spray voltage was set at 5.5 kV and supply temperature was 350°C. Declustering potential (DP): 96 eV for rosuvastatin and lovastatin; entrance potential (EP): 10 eV for rosuvastatin and IS. The optimized collision power was 45 eV for rosuvastatin and 31 eV for IS. Collision cell exit potential (CXP):14 eV for rosuvastatin and eight eV for IS.
Technique Validation
The strategy was validated for specificity, linearity, sensitivity, accuracy, precision, absolute restoration, matrix impact, and stability in response to the FDA pointers for validation of bioanalytical strategies.15
Specificity
The specificity was investigated by making ready and analyzing six particular person clean plasma samples from rats, a typical plasma pattern of rosuvastatin and an actual plasma pattern from rats after rosuvastatin administration.
Linearity
Linearity was assessed by making ready and analyzing a clean pattern and customary rosuvastatin samples within the vary ~2–2000μg·L−1. Calibration curves have been constructed from the height space ratios of rosuvastatin to IS vs plasma concentrations utilizing a weighted linear least-squares regression mannequin. The correlation coefficient shouldn’t exceed 0.99, and the relative error and precision of all calibration requirements should be inside 15%, besides on the decrease restrict of quantification (LLOQ), the place it shouldn’t deviate by greater than ±20% and rosuvastatin might be detected with a signal-to-noise ratio of 5.
Accuracy and Precision
Accuracy and precision have been assessed by evaluating high quality management (QC) samples at 4 focus ranges (six samples for every focus) on six completely different validation days. Precision was decided because the relative customary deviation (RSD), and accuracy was expressed as a proportion of the measured focus over the nominal (theoretical) focus. The RSD didn’t exceed 15% and the accuracy was inside 15% of the particular worth.
Restoration
Absolutely the restoration (extraction effectivity) of analytes from rat plasma was decided by evaluating the height areas of 5 processed low, medium and excessive QC samples with these of the non-extracted pure customary that symbolize 100% restoration on the similar theoretical concentrations of rosuvastatin.
Matrix Results
Matrix results have been quantitatively assessed utilizing 5 a lot of clean matrix at low, medium, and excessive QC concentrations (4, 160, 1600 μg·L−1). Three completely different units of options have been ready: a pure customary resolution of the analyte and IS in quintuplicate within the cell section injected immediately into the column (A), 5 completely different clean plasma spiked with the analyte and IS after extraction (B), and 5 completely different clean plasma spiked with the analyte and IS earlier than extraction (C). The matrix issue (MF) was calculated for every lot of matrix, by calculating the ratio of the height space within the presence of matrix (B) to the height space within the absence of matrix (A). The IS normalized MF was calculated by dividing the MF of the analyte by the MF of the IS. The coefficient of variation (CV) of the IS-normalized MF calculated from the 5 a lot of matrix shouldn’t be higher than 15%.
Stability
The soundness of rosuvastatin in QC samples (4, 160, 1600 μg·L−1) was validated by 4 research: short-term stability for 12 h in plasma, 30 days’ stability at –20°C, three freeze-thaw cycles and autosampler stability of 24 h of QC samples. The samples have been concluded to be steady if the bias of the steadiness samples was no more than ±15% of the nominal focus.
Assay of Plasma Concentrations of Rosuvastatin
A quantity of 10 μL of the working resolution of lovastatin (1mg·L−1 in methanol) was added to every Eppendorf tube (1.5 mL) containing 100μL of rat plasma, vortexed for 1 min; then 500 μL of methyl tert-butyl ether (containing 0.1% formic acid) was added to the samples. Samples have been shaken for five min and centrifuged for 8 min at 10,000 r·min−1 (5415R centrifuge; Eppendorf, Germany). Then 450 μL of the supernatant was then transferred to a different tube the place it was evaporated to finish dryness beneath a delicate stream of nitrogen fuel by decompression at room temperature. The samples have been reconstituted with 100 μL of cell section, vortexed for five min, and centrifuged for 8 min at 10,000 r·min−1. A quantity of 10 μL of the supernatant was injected immediately into the LC/MS/MS system for evaluation.
In vivo Examine
Topics
Wholesome and clear feminine and male SD rats, weighing ~220–250g, have been bought from the Zhejiang Academy of Medical Sciences. The research was accepted by the Animal Ethics Committee of the Zhejiang Academy of Medical Sciences (approval quantity: 2018–100).
Drug Therapies
The calcium pill of rosuvastatin (lot 1902A44) was provided by AstraZeneca Pharmaceutical Co., Ltd. WZ (lot180301), which accommodates 11.25 mg of Schisantherin A per capsule, was bought from Sichuan Hezheng Pharmaceutical Co., Ltd. (China). Rosuvastatin calcium gavage resolution was ready by dissolving the rosuvastatin calcium pill powder in suspension with 0.5% sodium carboxymethylcellulose resolution (25 mg/25mL) by ultrasound. The WZ gavage resolution was ready by dissolving the WZ contents after eradicating the capsule shell into suspension with 0.5% sodium carboxymethylcellulose resolution (375.0 mg/25 mL) by ultrasound.
Examine Design
Eighteen SD male rats have been randomly divided into three teams. Adaptive feeding was carried out for 1 week earlier than the experiment. The rats fasted for 12 h and got free entry to water. The management group acquired rosuvastatin 10 mg·kg−1 by gavage feeding. The only-dose group acquired a single dose of WZ contents 150 mg·kg−1 by gavage feeding, then took rosuvastatin 10 mg·kg−1 by gavage feeding quarter-hour later. The a number of dose group acquired consecutive every day doses of WZ contents 150 mg·kg−1 by gavage feeding for 7 days, then took rosuvastatin 10 mg·kg−1 by gavage feeding quarter-hour later the seventh day. Moreover, 18 SD feminine rats have been randomly divided into three teams and handled the identical approach as SD male rats.
Pattern Assortment
Roughly 0.5 mL of blood was collected from the orbital venous plexus of rats earlier than the consumption of rosuvastatin and at 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0 and 24.0 h after the dosing of rosuvastatin. Blood samples have been positioned in heparinized tubes and centrifuged at 3000 ×g for 10 min, and plasma was separated and saved at –20°C till assays have been carried out.
Statistics
Pharmacokinetic parameters have been calculated utilizing PhoenixTM WinNonlin® software program (Model 6.1, Pharsight, Mountain View, California, USA) with the non-compartmental technique. The utmost plasma concentrations (Cmax) and the occasions at which they occurred (Tmax) have been decided by inspection of the plasma concentration-time profile. The terminal elimination fee fixed (λz) was decided by linear regression of the terminal portion of the log concentration-time profile. The elimination half-life (T1/2) was calculated as 0.693/λz. The world beneath the plasma concentration-time curve (AUC) was decided by trapezoidal rule and extrapolated to infinity by calculation of Ct/λz. The pharmacokinetic parameters between teams have been statistically analyzed utilizing SPSS 21.0 software program utilizing a paired t check (two-tailed). Knowledge have been reported as imply ± customary deviation (SD). A P-value < 0.05 was thought of statistically vital.
Outcomes
Validation of the Bioanalytical Technique
The assay technique was particular. Endogenous chemical substances didn’t intervene with the willpower of rosuvastatin and IS (Figure 1). The calibration curves have been linear within the vary of ~2–2000 μg·L−1 (r2=0.9986, n=6), with a LLOQ of two μg·L−1 (RSD=7.75%, n=6). The within-and between-day CV of the QC samples at low, medium, and excessive concentrations have been lower than 10%. The common restoration of rosuvastatin was 100.1%, whereas the common absolute recoveries of rosuvastatin and IS have been 91.9% and 92.5%, respectively. The CV of the IS-normalized MF didn’t exceed 9.36% for rosuvastatin. No vital matrix results have been noticed. The soundness of rosuvastatin in plasma was confirmed by 4 research: short-term stability for 12 h in plasma, 30-day stability at –20°C, three freeze-thaw cycles and autosampler stability for twenty-four h of QC samples. All bias values between the measured worth and the nominal worth have been within the vary of −13.14% to six.99%. Specificity, linearity, sensitivity, accuracy, precision, restoration, stability, and matrix results met the necessities for a pharmacokinetic research.
Focus-Time Curves and Pharmacokinetics of Rosuvastatin
The imply plasma rosuvastatin focus time profiles in female and male rats are proven in Figures 2 and 3, respectively. The principle pharmacokinetic parameters in male rats and feminine rats are given in Tables 1 and 2, respectively. For each male rats and feminine rats, there have been no statistically vital variations in pharmacokinetic parameters between the management group, the single-dose group and the multidose group. Moreover, there was no statistically vital distinction in rosuvastatin pharmacokinetic parameters between the male management group and the feminine management group.
Desk 1 Pharmacokinetic Parameters of Rosuvastatin in Male Rats |
Desk 2 Pharmacokinetic Parameters of Rosuvastatin in Feminine Rats |
Dialogue
Rosuvastatin is minimally metabolized by cytochrome P450 isozymes (CYP). It’s eradicated by biliary excretion.16 The hepatic uptake of rosuvastatin is mediated by OATP1B1 whereas the biliary excretion mechanism is expounded with BCRP.13,14 There are inconsistent findings on whether or not P-glycoprotein (P-gp) contributes to rosuvastatin pharmacokinetics.17–19
The principle lively elements of WZ embrace Schisandrin A, Schisandrin B, Schisantherin A, Schisandrin C, Schisandrol A, and Schisandrol B.20 Every capsule of WZ accommodates 11.25 mg Schisantherin A and the content material of Schisandrin A was used as a high quality management indicator. Research have discovered that lignans in Schisandra sphenanthera have an inhibitory impact on CYP3A4 and have an apparent impact on tacrolimus and cyclosporine pharmacokinetics.21,22 Moreover, Schisandrin A may inhibit P-gp-mediated drug transport at gene and protein ranges.23 Schisandrin A and Schisandrin B may induce OATP1B1 expression and enhance its transporter exercise within the human hepatocellular liver carcinoma cell line.24 Schisandrin B may promote the in vitro uptake of rosuvastatin mediated by OATP1B1.11 Schisandrin A is a substrate of BCRP and could be transported by BCRP into Lilly Laboratories cell porcine kidney 1 (LLC-PK1) /BCRP cells whereas Schisandrol B may exhibit a marked inhibitory impact on BCRP transport perform.12 Due to this fact, WZ ingestion could intervene OATP1B1 and/or BCRP-mediated drug transportation of rosuvastatin in vivo.
To our data, that is the primary research to analyze the pharmacokinetic interplay between WZ and rosuvastatin in vivo. WZ had no impact on the primary pharmacokinetic parameters of rosuvastatin, which might be defined by the mixed impact of WZ on efflux transporters (ie, BCRP, P-gp) and the lively uptake transporter OATP1B1 in rats. Pharmacokinetic research confirmed that WZ had apparent inhibitory results on the bioavailability of atorvastatin in feminine rats however not in male rats,25 and a single dose of WZ may have an effect on the pharmacokinetic parameters of simvastatin and simvastatin acid in rats.26 Atorvastatin and simvastatin are extensively metabolized by CYP3A4, due to this fact their destiny within the physique is liable to lignans in Schisandra sphenanthera. It signifies that rosuvastatin might be an alternative choice to atorvastatin and simvastatin within the case of opposed drug reactions attributable to vital pharmacokinetic interactions when the mixture of WZ and statin is clinically wanted.
There was no statistically vital sex-based distinction within the pharmacokinetic parameters of rosuvastatin after rosuvastatin alone administration. The outcomes of this research are in step with the findings that rosuvastatin doesn’t produce clinically vital pharmacokinetic variations in Chinese language sufferers of various intercourse.19,27
The restrictions of this research are the next. First, the dose results of rosuvastatin on the pharmacokinetic interplay between herb and drug weren’t investigated. We examined the DDI potential on the dose of rosuvastatin 10 mg/kg in response to the research by Liu et al28 however didn’t examine the consequences at completely different doses of rosuvastatin (eg, 0.83 mg kg−1, 5 mg kg−1, or 100 mg kg−1).29–31 Secondly, we chosen rosuvastatin powder somewhat than rosuvastatin pill formulation, which may overcome any bias within the affect of excipients in pharmaceutical preparations of rosuvastatin. Nonetheless, the administration of rosuvastatin within the management group, single-dose group, and multigroup was constant; due to this fact, the related bias was negligible. Third, the interplay between cell-based metabolism and in vitro transport assessments has not been studied, and details about whether or not the drug transport mediated by particular transporters is influenced by WZ has not been outlined, however it’s anticipated to be explored in future research. Fourth, there was no research of rosuvastatin on the pharmacokinetics of lively natural elements of WZ. The pharmacokinetic research of herbs is also thought of of nice significance, and understanding the interplay between natural medication and chemical medicine ought to be additional deepened. Lastly, though our research offers some implications for rational drug use in scientific follow, it centered solely on the pharmacokinetic interplay between WZ and rosuvastatin. It’s essential to carry out an applicable pharmacodynamic research to substantiate whether or not there are adjustments in pharmacodynamic exercise and thus present extra help for our findings encouraging the protected use of this mixture. Moreover, this DDI research was performed in wholesome rats, and the circumstances of average hepatic impairment have to be additional investigated. Extension of the outcomes of pharmacokinetic interactions in rats to scientific sufferers should be confirmed by randomized scientific trials or real-world information in drug mixture remedy.
Conclusions
On this research, WZ, a proprietary Chinese language medication ready from the ethanolic extract of S. sphenanthera, had no apparent detrimental impact on the pharmacokinetics of rosuvastatin, and thus rosuvastatin can be utilized as an alternative choice to atorvastatin when WZ is clinically indicated along with statins. An appropriate pharmacodynamic research is required to encourage the protected use of this mixture.
Knowledge Sharing Assertion
Knowledge will probably be out there from the corresponding writer upon request.
Ethics Approval and Consent to Take part
The research protocol for animal experiments was accepted by the Experimental Animal Welfare Ethics Committee of the Zhejiang Academy of Medical Sciences (approval quantity: 2018-100) and conformed to the rules of the Nationwide Institutes of Well being Tips for the Care and Use of Laboratory Animals. Each effort was made to attenuate the ache, struggling, and dying of animals.
Acknowledgments
We thank Hui-chao Chang and Pei-fang Huang for his or her sort assist.
Creator Contributions
All authors made a major contribution to the work reported, whether or not that’s within the conception, research design, execution, acquisition of knowledge, evaluation and interpretation, or in all these areas; took half in drafting, revising or critically reviewing the article; gave ultimate approval of the model to be printed; have agreed on the journal to which the article has been submitted; and comply with be accountable for all points of the work.
Disclosure
The authors report no potential conflicts of curiosity on this work.
References
1. Chen Z, Liu F, Zheng N, et al. Wuzhi capsule (Schisandra Sphenanthera extract) attenuates liver steatosis and irritation throughout non-alcoholic fatty liver illness improvement. Biomed Pharmacother. 2019;110:285–293. doi:10.1016/j.biopha.2018.11.069
2. Tabrizi R, Tamtaji OR, Mirhosseini N, et al. The consequences of statin use on inflammatory markers amongst sufferers with metabolic syndrome and associated problems: a scientific assessment and meta-analysis of randomized managed trials. Pharmacol Res. 2019;141:85–103. doi:10.1016/j.phrs.2018.12.010
3. Ballantyne CM, Stein EA, Paoletti R, Southworth H, Blasetto JW. Efficacy of rosuvastatin 10 mg in sufferers with the metabolic syndrome. Am J Cardiol. 2003;91(5A):25C–27C. doi:10.1016/s0002-9149(03)00006-7
4. Lv J, Ren C, Hu Q. Impact of statins on the remedy of early diabetic nephropathy: a scientific assessment and meta-analysis of 9 randomized managed trials. Ann Palliat Med. 2021;10:11548–11557. doi:10.21037/apm-21-2673
5. Deedwania PC, Hunninghake DB, Bays HE, et al. Results of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in sufferers with traits of the metabolic syndrome. Am J Cardiol. 2005;95:360–366. doi:10.1016/j.amjcard.2004.09.034
6. Habte ML, Melka DS, Degef M, Menon MKC, Yifter H, Feyisa TO. Comparability of lipid profile, liver enzymes, creatine kinase and lactate dehydrogenase amongst kind II diabetes mellitus sufferers on statin remedy. Diabetes Metab Syndr Obes. 2020;13:763–773. doi:10.2147/DMSO.S234382
7. Feher M, Greener M, Munro N. Persistent hypertriglyceridemia in statin-treated sufferers with kind 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2013;6:11–15. doi:10.2147/DMSO.S35053
8. Jose J. Statins and its hepatic results: newer information, implications, and altering suggestions. J Pharm Bioallied Sci. 2016;8(1):23–28. doi:10.4103/0975-7406.171699
9. Kamal S, Khan MA, Seth A, et al. Useful results of statins on the charges of hepatic fibrosis, hepatic decompensation, and mortality in continual liver illness: a scientific assessment and meta-analysis. Am J Gastroenterol. 2017;112:1495–1505. doi:10.1038/ajg.2017.170
10. Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated opposed results and drug-drug interactions within the scientific setting of dyslipidemia. Am J Cardiovasc Medicine. 2010;10:11–28. doi:10.2165/13168600-000000000-00000
11. Lu Y, Hu Q, Chen L, et al. Interplay of deoxyschizandrin and schizandrin B with liver uptake transporters OATP1B1 and OATP1B3. Xenobiotica. 2019;49:239–246. doi:10.1080/00498254.2018.1437647
12. Wu L, Liu J, Hou J, et al. Interactions of the most important efficient parts in Shengmai components with breast most cancers resistance protein on the mobile and vesicular ranges. Biomed Pharmacother. 2021;133:110939. doi:10.1016/j.biopha.2020.110939
13. Kitamura S, Maeda Okay, Wang Y, Sugiyama Y. Involvement of a number of transporters within the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008;36:2014–2023. doi:10.1124/dmd.108.021410
14. Hua WJ, Fang HJ, Hua WX. Transepithelial transport of rosuvastatin and impact of ursolic acid on its transport in Caco-2 monolayers. Eur J Drug Metab Pharmacokinet. 2012;37:225–231. doi:10.1007/s13318-012-0094-9
15. US Meals and Drug Administration. Steering for Trade: Bioanalytical Technique Validation. Rockville, MD: US Division of Well being and Human Companies, Meals and Drug Administration, Heart for Drug Analysis and Analysis; 2018.
16. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW. Lack of impact of ketoconazole on the pharmacokinetics of rosuvastatin in wholesome topics. Br J Clin Pharmacol. 2003;55:94–99. doi:10.1046/j.1365-2125.2003.01720.x
17. Hua WJ, Hua WX, Fang HJ. The position of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins. Cardiovasc Ther. 2012;30:e234–e241. doi:10.1111/j.1755-5922.2011.00290.x
18. Li J, Volpe DA, Wang Y, et al. Use of transporter knockdown Caco-2 cells to analyze the in vitro efflux of statin medicine. Drug Metab Dispos. 2011;39:1196–1202. doi:10.1124/dmd.111.038075
19. Zhou Q, Ruan ZR, Yuan H, Xu DH, Zeng S. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. Pharmazie. 2013;68:129–134.
20. Qin XL, Chen X, Zhong GP, et al. Impact of Tacrolimus on the pharmacokinetics of bioactive lignans of Wuzhi pill (Schisandra sphenanthera extract) and the potential roles of CYP3A and P-gp. Phytomedicine. 2014;21:766–772. doi:10.1016/j.phymed.2013.12.006
21. Wei H, Tao X, Di P, et al. Results of conventional Chinese language medication Wuzhi capsule on pharmacokinetics of tacrolimus in rats. Drug Metab Dispos. 2013;41:1398–1403. doi:10.1124/dmd.112.050302
22. Xue XP, Qin XL, Xu C, et al. Impact of Wuzhi pill (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. Phytother Res. 2013;27:1255–1259. doi:10.1002/ptr.4849
23. Zhang ZL, Jiang QC, Wang SR. Schisandrin A reverses doxorubicin-resistant human breast most cancers cell line by the inhibition of P65 and Stat3 phosphorylation. Breast Most cancers. 2018;25:233–242. doi:10.1007/s12282-017-0821-9
24. Guo CX, Deng S, Yin JY, Liu ZQ, Zhang W, Zhou HH. Schisandrin A and B induce natural anion transporting polypeptide 1B1 transporter exercise. Pharmazie. 2015;70:29–32.
25. Shi QL. Results of Wuzhi capsule on pharmacokinetics of atorvastatin. Fudan College; 2014.
26. Solar Q, Solar JF, Li L, Chang HC, Zhou Q. Results of Wuzhi capsule on the pharmacokinetics of simvastatin and its metabolite simvastatin acid in rats. Chin J Clin Pharmacol Ther. 2020;25:1242–1249.
27. Chen J, Lou H, Jiang B, et al. Results of meals and gender on pharmacokinetics of rosuvastatin in a Chinese language inhabitants based mostly on 4 bioequivalence research. Clin Pharmacol Drug Dev. 2020;9(2):235–245. doi:10.1002/cpdd.706
28. Liu JM, Ye XY, Liu ZJ, Wen JH, Wang F. Impact of scutellarin on the pharmacokinetics of rosuvastatin in rats. Chin J Clin Pharmacol. 2017;33:1003–1006.
29. Yang J, Hasegawa J, Endo Y, Iitsuka Okay, Yamamoto M, Matsuda A. Pharmacokinetic drug interplay between rosuvastatin and Tanjin in wholesome volunteers and rats. Yonago Acta Med. 2019;62:77–84. doi:10.33160/yam.2019.03.011
30. Basu S, Jana S, Patel VB, Patel H. Results of piperine, cinnamic acid and gallic acid on rosuvastatin pharmacokinetics in rats. Phytother Res. 2013;27:1548–1556. doi:10.1002/ptr.4894
31. Wen JH, Xiong YQ. The impact of natural medication danshensu and ursolic acid on pharmacokinetics of rosuvastatin in rats. Eur J Drug Metab Pharmacokinet. 2011;36:205–211. doi:10.1007/s13318-011-0048-7